EndoParagon inc. believes that current medications used to treat patients with Chagas' Disease and other Neglected Tropical Diseases need to be replaced or optimized by the introduction of safer and more effective therapies.
EndoParagon inc. is a world-class leader in Drug Research & Development and will be responsible for introducing new treatments to cure patients of Chagas' Disease and other internal parasitic infections, including some Neglected Tropical Diseases.
EndoParagon inc. leads international efforts to advance Drug Research & Development towards safe and effective treatments for patients with Chagas' Disease and other internal parasitic infections. Through this endeavour, the Company will also foster rewarding collaborations with world-renowned research teams and offer much-needed hope to patients.
Deborah A. Nicoll-Griffith, Ph.D.